RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
DR REDDYS LABORATORIES LTD
Financials through fiscal 2025, year ended Mar 31, 2025
$13.08+0.01 (+0.08%)
Close on Oct 19, 2026
Share price
−$1.37 (−9.48%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Ex-dividend
DR REDDYS LABORATORIES LTD grew revenue 16.6% to ₹325.54B over fiscal 2025. Operating income rose 6.1% to ₹71.84B, moving the operating margin from 24.3% to 22.1%. Free cash flow was ₹18.92B, down 34.8% from a year earlier.
Revenue
₹325.54B
+16.6% vs. a year earlier
Operating income
₹71.84B
+6.1% vs. a year earlier
Free cash flow
₹18.92B
-34.8% vs. a year earlier
EPS, diluted
67.78 INR
+1.5% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Mar 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- ₹325.54B
- Net income
- ₹56.54B
- EPS, diluted
- 67.78 INR
- Free cash flow
- ₹18.92B
Valuation needs the share price. It fills in once daily prices are connected and converted from INR.
Ten years at a glance
Fiscal years 2016 to 2025, INR
Revenue
₹325.54B+16.6% YoY
Gross profit
₹190.43B+16.4% YoY
Operating income
₹71.84B+6.1% YoY
Net income
₹56.54B+1.5% YoY
EPS, diluted
67.78 INR+1.5% YoY
Free cash flow
₹18.92B-34.8% YoY
Reported period